The cost can reach upwards of $900 for just one months supply
This means patients and health providers have to monitor for changes and recalibrate accordingly
Long-term human safety data remains limited due to the compounds regulatory status
For now, the take-home messages for an informed patient or provider are: GLP-1 RAs (Ozempic, Wegovy, Mounjaro, etc.) are highly effective for T2D and obesity, offering glycemic control and substantial weight loss along with protective effects on the heart and possibly kidneys
Stymied by the low amount of GSH reaching the brain when given orally, researchers turned to intranasal administration
Because this is a demonstration program, the process may differ slightly from traditional Part D prescription coverage, but the intent is to keep the experience as simple as possible for beneficiaries